右微创开胸与正中胸骨切开术用于再次二尖瓣手术:观察性研究的系统综述与荟萃分析
该系统综述与荟萃分析检索MEDLINE和EMBASE至2017年11月1日,纳入6项回顾性观察研究共777例既往经胸骨切开行心脏手术的患者,比较右前外侧微创开胸(MT-MVS)与再次正中胸骨切开(ST-MVS)行二尖瓣手术的效果。汇总分析显示MT-MVS较ST-MVS降低死亡率(OR 0.41,95%CI 0.18-0.96;P=0.04)、缩短住院时间(均数差-3.81,95%CI -5.53至-2.08;P<0.0001)并减少因出血再手术(OR 0.32,95%CI 0.10-0.99;P=0.0488),卒中发生率相似(OR 1.51,95%CI 0.65-3.54;P=0.34),均无 heterogeneity。作者结论认为微创开胸再次二尖瓣手术是标准胸骨切开的 safe alternative,但因现有文献证据有限且质量低,需更多方法学严谨的随机对照试验。
要点
- 再次二尖瓣手术中,MT-MVS较ST-MVS降低死亡率(OR 0.41,95%CI 0.18-0.96;P=0.04)。
- MT-MVS较ST-MVS缩短住院时间(均数差-3.81,95%CI -5.53至-2.08;P<0.0001)并减少因出血再手术(OR 0.32,95%CI 0.10-0.99;P=0.0488)。
- 两组卒中发生率相似(OR 1.51,95%CI 0.65-3.54;P=0.34),汇总分析均无 heterogeneity。
核心结论
- 作者结论认为,经微创开胸行再次微创二尖瓣手术是标准胸骨切开的 safe alternative,可降低死亡率、缩短住院时间并减少因出血再手术,卒中风险相当。
- 作者同时指出,因现有文献证据有限且质量低,需更多方法学严谨的随机对照试验。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE和EMBASE数据库至2017年11月1日。
- 纳入6项回顾性观察研究,共777例既往经胸骨切开行心脏手术并接受再次二尖瓣手术的患者。
- 采用随机效应模型和I2检验进行荟萃分析。
主要发现
- MT-MVS较ST-MVS降低死亡率(OR 0.41,95%CI 0.18-0.96;P=0.04)。
- MT-MVS较ST-MVS缩短住院时间(均数差-3.81,95%CI -5.53至-2.08;P<0.0001)。
- MT-MVS较ST-MVS减少因出血再手术(OR 0.32,95%CI 0.10-0.99;P=0.0488)。
- 两组卒中发生率相似(OR 1.51,95%CI 0.65-3.54;P=0.34)。
- 汇总分析均无 heterogeneity。
关键数值与推荐
- 再次胸骨切开二尖瓣手术中血管结构损伤发生率为7-9%,并与死亡率增加相关。
- MT-MVS对比ST-MVS的死亡率OR 0.41(95%CI 0.18-0.96;P=0.04)。
- MT-MVS对比ST-MVS的住院时间均数差-3.81(95%CI -5.53至-2.08;P<0.0001)。
- MT-MVS对比ST-MVS的因出血再手术OR 0.32(95%CI 0.10-0.99;P=0.0488)。
- MT-MVS对比ST-MVS的卒中OR 1.51(95%CI 0.65-3.54;P=0.34)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 现有文献提供的是有限、低质量的证据。
- 需更多方法学严谨的随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reoperative mitral valve surgery (MVS) through a median sternotomy (ST-MVS) can be particularly challenging due to dense adhesions and is known to carry a substantial risk of injuries to vascular structures. These injuries occur in 7-9% of cases and are associated with increased mortality rates. A valid alternative that could avoid the risks associated with redo ST-MVS is the right anterolateral minithoracotomy (MT-MVS) approach. The aim of this study was to quantify the effects of MT-MVS compared with those of ST-MVS on morbidity and mortality among patients who underwent prior cardiac surgery through a sternotomy. The MEDLINE and EMBASE databases were searched through 1 November 2017. Data regarding mortality, stroke, reoperation for bleeding and length of hospital stay were extracted and submitted to a meta-analysis using random effects modelling and the I2-test for heterogeneity. Six retrospective observational studies were included, enrolling a total of 777 patients. In a pooled analysis, MT-MVS demonstrated reduced mortality rates compared to a standard sternotomy [odds ratio (OR) 0.41, 95% confidence interval (CI) 0.18-0.96; P = 0.04]. MT-MVS was, moreover, associated with reduced length of hospital stay [difference between the means was -3.81, 95% CI -5.53 to -2.08; P < 0.0001) and reoperation for bleeding (OR 0.32, 95% CI 0.10-0.99; P = 0.0488). The incidence of stroke was similar (OR 1.51, 95% CI 0.65-3.54; P = 0.34), all in the absence of heterogeneity. In conclusion, reoperative minimally invasive MVS through a minithoracotomy is a safe alternative to standard sternotomy, with reduced mortality rates, length of hospital stay and reoperations for bleeding and a comparable risk of stroke. However, because the existing literature provided limited, low-quality evidence, more methodologically rigorous randomized controlled trials are needed.
引用
- Daemen JHT, Heuts S, Olsthoorn JR, et al. Right minithoracotomy versus median sternotomy for reoperative mitral valve surgery: a systematic review and meta-analysis of observational studies. Eur J Cardiothorac Surg. 2018. PMID: 29688301. doi:10.1093/ejcts/ezy173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。